fluoxetine has been researched along with Kidney Diseases in 4 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Blood samples for the measurement of fluoxetine and its active metabolite norfluoxetine were drawn 13 times in the first 48 hr after dosing and thrice weekly thereafter for 4 wk." | 1.27 | Fluoxetine kinetics and protein binding in normal and impaired renal function. ( Aronoff, GR; Bergstrom, RF; Lemberger, L; Pottratz, ST; Sloan, RS; Wolen, RL, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kowal-Bielecka, O | 1 |
| Fransen, J | 1 |
| Avouac, J | 1 |
| Becker, M | 1 |
| Kulak, A | 1 |
| Allanore, Y | 1 |
| Distler, O | 1 |
| Clements, P | 1 |
| Cutolo, M | 1 |
| Czirjak, L | 1 |
| Damjanov, N | 1 |
| Del Galdo, F | 1 |
| Denton, CP | 1 |
| Distler, JHW | 1 |
| Foeldvari, I | 1 |
| Figelstone, K | 1 |
| Frerix, M | 1 |
| Furst, DE | 1 |
| Guiducci, S | 1 |
| Hunzelmann, N | 1 |
| Khanna, D | 1 |
| Matucci-Cerinic, M | 1 |
| Herrick, AL | 1 |
| van den Hoogen, F | 1 |
| van Laar, JM | 1 |
| Riemekasten, G | 1 |
| Silver, R | 1 |
| Smith, V | 1 |
| Sulli, A | 1 |
| Tarner, I | 1 |
| Tyndall, A | 1 |
| Welling, J | 1 |
| Wigley, F | 1 |
| Valentini, G | 1 |
| Walker, UA | 1 |
| Zulian, F | 1 |
| Müller-Ladner, U | 1 |
| Bobo, WV | 1 |
| Shelton, RC | 1 |
| Aronoff, GR | 1 |
| Bergstrom, RF | 2 |
| Pottratz, ST | 1 |
| Sloan, RS | 1 |
| Wolen, RL | 1 |
| Lemberger, L | 2 |
| Beasley, CM | 1 |
| Levy, NB | 1 |
| Blumenfield, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aiming to Reduce Disease-related Gastrointestinal Symptoms in Systemic Sclerosis by Repeat Intestinal Infusions of Anaerobic Cultivated Human Intestinal Microbiome (ACHIM); a Randomized, Double-blind Placebo-controlled 20 Week Study[NCT04300426] | Phase 2 | 75 participants (Actual) | Interventional | 2020-09-24 | Completed | ||
| "Effect of a Pulmonary Rehabilitation Program in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis on Oxygen Consumption, Functionality, and Quality of Life"[NCT06105073] | 67 participants (Anticipated) | Observational [Patient Registry] | 2022-03-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for fluoxetine and Kidney Diseases
| Article | Year |
|---|---|
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.
Topics: Adult; Age Factors; Antidepressive Agents; Benzodiazepines; Depression; Drug Combinations; Drug Inte | 2010 |
The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine.
Topics: Adult; Aged; Clinical Trials as Topic; Depressive Disorder; Dose-Response Relationship, Drug; Drug A | 1993 |
1 other study available for fluoxetine and Kidney Diseases
| Article | Year |
|---|---|
Fluoxetine kinetics and protein binding in normal and impaired renal function.
Topics: Administration, Oral; Blood Proteins; Fluoxetine; Half-Life; Humans; Kidney Diseases; Kinetics; Male | 1984 |